These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 29879920)

  • 1. Highly selective SGLT2 inhibitor dapagliflozin reduces seizure activity in pentylenetetrazol-induced murine model of epilepsy.
    Erdogan MA; Yusuf D; Christy J; Solmaz V; Erdogan A; Taskiran E; Erbas O
    BMC Neurol; 2018 Jun; 18(1):81. PubMed ID: 29879920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodropropizine suppresses seizure activity in rats with pentylenetetrazol-induced epilepsy.
    Erdogan MA; Yusuf D; Erdogan A; Erbas O
    Epilepsy Res; 2019 Feb; 150():32-37. PubMed ID: 30610970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats.
    Han S; Hagan DL; Taylor JR; Xin L; Meng W; Biller SA; Wetterau JR; Washburn WN; Whaley JM
    Diabetes; 2008 Jun; 57(6):1723-9. PubMed ID: 18356408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
    Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
    Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does SGLT2 inhibition with dapagliflozin overcome individual therapy resistance to RAAS inhibition?
    Petrykiv S; Laverman GD; de Zeeuw D; Heerspink HJL
    Diabetes Obes Metab; 2018 Jan; 20(1):224-227. PubMed ID: 28685934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats.
    Chen L; LaRocque LM; Efe O; Wang J; Sands JM; Klein JD
    Am J Med Sci; 2016 Nov; 352(5):517-523. PubMed ID: 27865300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin: glucuretic action and beyond.
    Balakumar P; Sundram K; Dhanaraj SA
    Pharmacol Res; 2014 Apr; 82():34-9. PubMed ID: 24705156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.
    Ott C; Jumar A; Striepe K; Friedrich S; Karg MV; Bramlage P; Schmieder RE
    Cardiovasc Diabetol; 2017 Feb; 16(1):26. PubMed ID: 28231831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
    Vivian EM
    Am J Health Syst Pharm; 2015 Mar; 72(5):361-72. PubMed ID: 25694411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunosuppressant Tacrolimus Treatment Delays Acute Seizure Occurrence, Reduces Elevated Oxidative Stress, and Reverses PGF2α Burst in the Brain of PTZ-Treated Rats.
    Pazarlar BA; Egilmez CB; Erdogan MA; Erbas O
    Neurochem Res; 2023 Jun; 48(6):1971-1980. PubMed ID: 36780043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Dapagliflozin Treatment on the Expression of Renal Sodium Transporters/Channels on High-Fat Diet Diabetic Mice.
    Ma C; de Baaij JHF; Millar PJ; Gault VA; de Galan BE; Bindels RJM; Hoenderop JGJ
    Nephron; 2019; 142(1):51-60. PubMed ID: 30799406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes.
    Nakamura Y; Nagai Y; Terashima Y; Nishine A; Ishii S; Kato H; Ohta A; Tanaka Y
    Expert Opin Pharmacother; 2015; 16(17):2553-9. PubMed ID: 26479189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin improves insulin resistance and glucose intolerance in a novel transgenic rat model of chronic glucose overproduction and glucose toxicity.
    Joannides CN; Mangiafico SP; Waters MF; Lamont BJ; Andrikopoulos S
    Diabetes Obes Metab; 2017 Aug; 19(8):1135-1146. PubMed ID: 28244693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dapagliflozin: an emerging treatment option in type 2 diabetes.
    Kipnes M
    Expert Opin Investig Drugs; 2009 Mar; 18(3):327-34. PubMed ID: 19243283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts.
    Lee TM; Chang NC; Lin SZ
    Free Radic Biol Med; 2017 Mar; 104():298-310. PubMed ID: 28132924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE; Heerspink HJL; Penland RC; Tang W; Boulton DW; Bachina S; Fox RD; Fenici P; Thuresson M; Mentz RJ; Hernandez AF; Holman RR
    Diabetes Care; 2019 Feb; 42(2):318-326. PubMed ID: 30523029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Anti-Seizure Effect of Liraglutide on Ptz-Induced Convulsions Through its Anti-Oxidant and Anti-Inflammatory Properties.
    Erdogan MA; Erdogan A; Erbas O
    Neurochem Res; 2023 Jan; 48(1):188-195. PubMed ID: 36040609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.